New drug duo aims to fight kidney cancer without losing the kidney

NCT ID NCT07584733

Not yet recruiting Disease control Sponsor: RenJi Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a two-drug treatment (disitamab vedotin plus tislelizumab) for people with a rare, aggressive cancer of the upper urinary tract that has a specific marker (HER2-positive). The goal is to shrink the tumor so that the kidney can be saved, avoiding complete removal. About 50 adults will receive the drugs before deciding on surgery, with the main focus on keeping the kidney cancer-free for at least one year.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for UPPER TRACT UROTHELIAL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

renal pelvis/ureter urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

UPPER TRACT UROTHELIAL CARCINOMA

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Ethics Committee of Shanghai Renji Hospital

Shanghai, Shanghai Municipality, China

Contact Phone: •••-•••-•••• Email: •••••@•••••